Eltrombopag is an oral thrombopoietin receptor agonist (TPO-RA) used to treat thrombocytopenia. Eltrombopag stimulates the differentiation and proliferation of megakaryocytes by binding to the thrombopoietin receptor (TPO-R), thereby increasing platelet production.
Indications:
1) Chronic immune thrombocytopenia (ITP):
Eltrombopag is used to treat adults and children with chronic immune thrombocytopenia who have not responded to treatment with corticosteroids, immunoglobulin, or splenectomy to help increase platelet counts and reduce the risk of bleeding.
2) Severe aplastic anemia (SAA):
Eltrombopag is indicated for the treatment of adult patients with severe aplastic anemia (SAA) who have not responded to immunosuppressive therapy, particularly when their platelet levels are very low.
3) Hepatitis C-related thrombocytopenia:
Eltrombopag is used to treat patients with thrombocytopenia due to hepatitis C to help maintain adequate platelet counts to continue antiviral treatment.
Advantages:
1) Oral administration, easy to use:
Eltrombopag is an oral medication that patients can take at home, reducing dependence on hospital facilities and improving the convenience of treatment and quality of life for patients.
2) Specific stimulation of platelet production:
As a TPO receptor agonist, eltrombopag can specifically stimulate megakaryocytes to produce platelets and effectively increase platelet counts, especially when traditional treatments are ineffective.
3) Multiple indications covered:
Eltrombopag is not only suitable for ITP patients, but is also effective for patients with severe aplastic anemia and hepatitis C-related thrombocytopenia, expanding its scope of application.
